Abstract: VKORC1 is a component of the enzyme that is the therapeutic target site of warfarin. In order to investigate the relationship between VKORC1 gene and warfarin dose response, we studied this gene in 22 clinically sensitive patients and 36 clinically normal patients as control group that in previous studies their blood warfarin levels were determined by HPLC and genotyped for CYP2C9. In the majority of these patients, the results had shown that the clinical phenotype was according to the CYP2C9 genotype, but there were sensitive patients with normal CYP2C9 genotype. So in this study for investigation of another reason of sensitivity to warfarin in these patients, VKORC1 was chosen. In order to determine the impact of VKORC1 1173C>T and 3730G>A polymorphisms in warfarin dose variability, a protocol of RFLP based PCR with HinfI and SsiI was used. Polymorphisms of VKORC1 were effective factors in sensitivity to warfarin in the majority of them. However, in some of sensitive patients, there was inconformity of clinical phenotypes with CYP2C9 and VKORC1 genotypes. In conclusion, our findings suggest that CYP2C9 and VKORC1 are not the only effective factors in sensitivity to warfarin and more studies are necessary for investigation of sensitivity reasons in these patients.
INTRODUCTION
Warfarin is currently the most widely used oral anticoagulant drug for the prevention and treatment of patients with arterial and venous thromboembolic disorders (Hirsh et al., 2001). However, the use of this drug is accompanied by considerable problems because of the high interindividual variability, as well as intraindividual variability in dose requirement (Takahashi et al., 2003). To achieve and maintain an optimal warfarin dose, the prothrombin time and the International Normalized Ratio (INR) are monitored and doses are adjusted to maintain the patients INR within a narrow therapeutic range. The target INR depends on the indication of warfarin treatment. For most indications, the ideal INR value lies between 2.0 and 3.0 (Horton and Bushwick, 1999). The large variability in warfarin response is multifactorial.
Polymorphisms in the gene encoding the cytochrome P-450 2C9 enzyme (CYP2C9) are known to contribute to variability in sensitivity to warfarin (Kim et al., 2009). CYP2C9 is the enzyme primarily responsible for the metabolic clearance of the S-enantiomer of warfarin. A number of polymorphisms in CYP2C9 have been identified, but the most important are CYP2C9*2 (R144C) and CYP2C9*3 (I359L). However, allelic variants of CYP2C9 cannot fully explain the large interindividual and interethnic differences in warfarin dose requirements, suggesting that additional factor(s) may contribute to this variability (Takahashi et al., 2004).
The presence of polymorphisms in the Vitamin K epoxide reductase subunit 1 gene (VKORC1) has been recently identified as another cause of variability in the response to warfarin in many populations (Kim et al., 2009). VKORC1 recycles vitamin K epoxide to the reduced form of vitamin K, an essential cofactor in the formation of the active clotting factors II, VII, IX and X through γ-glutamyl carboxylation .Warfarin inhibits VKORC1 activity by reducing the regeneration of vitamin K and thus exerting its anticoagulation effect (Cain et al., 1997). Several studies have been shown association between VKORC1 polymorphisms and reduction of warfarin dose requirement and warfarin sensitivity (DAndrea et al., 2005; Geisen et al., 2005; Yuan et al., 2005; Lee et al., 2006). To date, numerous Single Nucleotide Polymorphisms (SNPs) have been identified in the VKORC1 gene. Among these SNPs, two common polymorphisms, a C>T transition at position 1173 (rs9934438) in intron 1 and 3730G>A transition in the 3'-untranslated region [UTR] (rs7294) in VKORC1 gene, affect the interindividual variability of warfarin dose (DAndrea et al., 2005). In some of populations the SNP 1173C>T has been reported to be associated with the low dose warfarin phenotype (Limdi et al., 2008) and patients carrying at least one 1173T allele have an increased risk of bleeding compared to those with the CC genotype (Reitsma et al., 2005). In addition, it has been shown that the SNP 3730G>A was associated with higher warfarin dose requirement (DAndrea et al., 2005).
Genetic polymorphisms involved in both pharmacokinetic (e.g., CYP2C9) and pharmacodynamic (e.g., VKORC1) factors. Therefore, appear to interplay in the overall interindividual variability of warfarin doses; moreover, the contribution of each factor may differ among different ethnic populations (Yin and Miyata, 2007).So for the first time in this study, the effect of VKORC1 1173C>T and 3730G>A polymorphism in variability of warfarin requirement in some of Iranian warfarin sensitive patients was investigated.
MATERIALS AND METHODS
This project has been conducted at Alzahra University since 2008.
In this study, 58 treated patients with warfarin were recruited from Imam Khomeini Hospital (Tehran-Iran) for participation in this trial. The study group clinically sensitive patients (22 patients) were selected by participating centers according to the following criteria:
| • | Adult-patients who need less than 10.5 mg week-1 of warfarin to keep the INR in therapeutic range (INR = two - three) |
| • | Patients who were on usual dose of warfarin (5-15 mg day-1) but they had bleeding or INR>4 either in seven days after cessation of warfarin or three days after receiving 3 mg day-1 vitamin K1 intravenously |
The first criterion was chosen from previous reports (Linder, 2001) and the second was chosen by our group while encountered such patients in clinic. The control group (36 adult patients) was randomly selected from patients who took warfarin for various causes and showed normal response to warfarin. In order to determine the impact of 1173C>T and 3730G>A SNPs in VKORC1, a protocol of RFLP (Restriction Fragment Length Polymorphism) based PCR was used. DNA was extracted from whole blood samples using the DNG-PlusTM kit (Fermentas).
Primers 1173F (5'TGACATGGAATCCTGACGTG3') and 1173R (5'GAGCTGACCAAGGGGGAT3' ) for amplification of 361 base pairs (bp) from intron one of VKORC1 gene (DAndrea et al., 2005), also primers 3730F (5'AGCCTGATGTGGCTCAGTTT3') and 3730R (5'GTGTGGCACATTTGGTCCATT3') for amplification of 226 bp from the 3'UTR of VKORC1 gene were selected (Li et al., 2006). DNA samples were amplified by PCR in a final volume of 15 μL, with 7.5 μL PCR Master Mix (Ampliqon), 0.5 mM each primer, 0.3 μg genomic DNA. Amplification conditions consisted of an initial denaturation of 10 min at 94°C, followed by 30 PCR cycles in 30 sec at 94°C, 30 sec at 58°C and, 90 sec at 72°C with a final extension of 5 min at 72°C. PCR products of these fragments (2 μg from each) were digested with 10 units of Hinf I and SsiI (AciI), respectively in a final volume of 30 μL in the appropriate digestion buffer at 37°C for 16 h. The digested products were visualized on 8% poly acryl amide gels stained with ethidium bromide.
All the Statistical analyses were performed using SPSS for Windows, version 11.5. Multiple comparisons between different CYP2C9 and VKORC1 haplotypes were made using univariate analysis (ANOVA), the unequal variance t-test and Post-Hot tests. Results are presented as Mean±SD unless stated otherwise. A p-value of less than 0.05 was taken as statistically significant.
RESULTS
PCR product of 1173C>T region contained 361 bp. There was one recognition site in position eight for restriction enzyme HinfI in wild type genotype (homozygote CC) so that two fragments (353 and 8 bp) are formed upon HinfI digestion. The 1173T allele created another HinfI recognition site in position 59 and three fragments (310, 43 and 8 bp) in mutant homozygous (TT) and four fragments (353, 310, 43 and 8 bp) in heterozygote genotype (CT) were resulted by HinfI digestion. PCR product of 3730G>A region contain 226 bp. There was one recognition site in position 195 for restriction enzyme SsiI in wild type genotype (homozygote GG) so that two fragments (195 and 31 bp) are formed upon SsiI digestion. In the present of mutation (3730A allele), SsiI has no recognition site and thus one fragment (226 bp) in mutant homozygote (AA) and three fragments (226, 195 and 31 bp) in heterozygote genotype (GA) are formed upon SsiI digestion. There was not wild type genotype (GG) in our samples.
The genotype information was achieved from the band cleavage patterns (Fig. 1, 2). Genotype distributions of CYP2C9 allele variants (*1*1,*1*2, *2*2), 1173C>T and 3730G>A SNPs in VKORC1, mean weekly warfarin dose requirements and blood warfarin concentrations in all patients are summarized in Table 1.
| Fig. 1: | Acryl amide gel electrophoresis of PCR-RFLP in 1173C>T
region with restriction enzyme HinfI. Lane 1: DNA ladder molecular
size marker (100 bp), Lanes 2, 3, 4: 1173 TT, Lanes 5, 6: 1173 CT, Lanes
7, 8, 9: 1173 CC |
| Fig. 2: | Acryl amide gel electrophoresis of PCR-RFLP in 3730G>A
region with restriction enzyme SsiI. Lane1: DNA ladder molecular
size marker (100 bp), Lanes 2, 5: 3730 AA , Lanes 3, 4, 6, 7 and 8: 3730
GA |
As shown, mean weekly warfarin doses in carriers of CYP2C9*1*2 and *2*2 are significantly lower (p = 0.006) like patients with 1173CT and TT, in contrast to carriers of 3730AA that need higher doses.
| Table 1: | Relationship between CYP2C9 and VKORC1 genotype distributions and pharmacokinetics of warfarin |
n: No. of patients, INR: International Normalized Ratio, Conc:
Concentration. A p-value of less than 0.05 was taken as statistically significant.
*In literatures, CYP2C9 genotypes are shown by this symbol |
|
| Table 2: | Relationship between CYP2C9 and VKORC1 genotype distributions and warfarin sensitivity in patients |
Mean concentration of warfarin in patients blood with CYP2C9*1*1 is lower than others with *1*2 variant. Mean concentration of warfarin in the blood of TT carriers is lower than CT and CC carriers (Table 1). The frequencies of the allele variants CYP2C9 and 1173C>T and 3730G>A SNPs in VKORC1 gene between sensitive and normal patients were shown in Table 2. There were significant differences (p<0.001) in mean warfarin doses between sensitive and normal patients. According to these results, 68.1 and 81.8% of sensitive patients to warfarin have CYP2C9 variant and VKORC1 1173T allele respectively. The frequency of CYP2C9*2*2 was as expected low (6.9%) whereas the frequency of homozygote for VKORC1 1173TT genotype was 17.2% (Table 2).
DISCUSSION
The use of the same fixed dose of warfarin for all patients is unachievable because the responsiveness of different patients to warfarin is highly variable.
| Table 3: | Relationship between Clinical phenotype and CYP2C9/VKORC1 genotypes |
| n: No. of patients | |
Therefore, some patients require less warfarin dose than others warfarin sensitive patients and some of them need more warfarin dose warfarin resistant patients. In many populations CYP2C9 andVKORC1 polymorphisms are important to sensitivity to warfarin (Yuan et al., 2005; Kirchheiner and Brockmoller, 2005; Scott et al., 2008; Wen et al., 2008).
In our previous studies (Ghadam et al., 2009), all patients that used in this study were genotyped for CYP2C9*2 and *3 and in another study the concentration of warfarin in the patient's blood was determined by HPLC (Sadrai et al., 2008). In these population, there were sensitive patients but with wild type CYP2C9 genotype (*1*1). This study was designed to investigate the effect of VKORC1 gene polymorphisms and their relationship to warfarin dose and sensitivity to warfarin in these Iranian warfarin sensitive patients with CYP2C9 *1*1. As it was shown in Table 3, on the basis of CYP2C9 genotype and clinical phenotype, a total of 58 warfarin treated patients were divided in four different groups that genotyped for 1173C>T and 3730G>A SNPs in VKORC1 gene. Consist to the previously published observations (Aithal et al., 1999; Henne et al., 1998; Kamali et al., 2004) our results showed that, majority of sensitive patients have mutation in CYP2C9. Also like studies Takahashi et al. (2006) and Osman et al. (2006) studies our findings confirmed that VKORC1 polymorphism in 1173C>T is effective factor in sensitivity to warfarin in the majority of sensitive patients. But, in contrast to the previous findings which showed that the SNP 3730G>A was associated with higher warfarin dose requirement (DAndrea et al., 2005) in this study, the patients with SNP 3730G>A need normal or even lower level of warfarin.
Therefore, the VKORC1 1173T allele accounts for low dosage requirements of most patients with CYP2C9 *1*1. However, in some sensitive patients with wild type CYP2C9, there was not mutation in 1173 position of VKORC1. This means that these polymorphisms in CYP2C9 and VKORC1 are not the only effective factors in sensitivity to warfarin, so more investigations should be done in the Iranian patients who have normal CYP2C9 and VKORC1 genotypes but with sensitivity to warfarin until recognized the cause(s) of their sensitivity.
ACKNOWLEDGMENTS
The Vice Chancellor for Research of Alzahra University supported this study. The authors wish to thank Imam Khomeini hospital, Cellular and Molecular Biology Research Center of Shahid Beheshti University, M.C and the Biopharmacutics and Pharmacokinetics Laboratory of Tehran University of Medical Sciences.